Yongji Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yongji Liu has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Chuanwu Jiang
Department of Radiology, The Affiliated Qingdao Hiser Hospital of Qingdao University (Qingdao Hospital of Traditional Chinese Medicine), Qingdao, Shandong, China
4 shared publicationsHongxing Han
Department of Neurology, Linyi People's Hospital, Linyi, Shandong, China
4 shared publicationsBo Xu
Department of Neurology, Provincial Hospital of Shandong University, Jinan, Shandong, China
2 shared publications- Fang Ju
Department of Oncology, Qingdao Central Hospital, Qingdao, Shandong, China
2 shared publications Guoping Jiang
Department of Neurosurgery, The Affiliated Qingdao Hiser Hospital of Qingdao University (Qingdao Hospital of Traditional Chinese Medicine), Qingdao, Shandong, China
2 shared publicationsLing Shi
Department of Neurosurgery, The Affiliated Qingdao Hiser Hospital of Qingdao University (Qingdao Hospital of Traditional Chinese Medicine), Qingdao, Shandong, China
2 shared publications
Latest Publications
- Retraction
- 23 January 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 196, 118991
Retraction notice to “Activation of PPARγ mediates icaritin-induced cell cycle arrest and apoptosis in glioblastoma multiforme” [Biomed. Pharmacother. 100 (2018) 358–366]
- 23 January 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 196, 118991
RetractionRetraction notice to “Activation of PPARγ mediates icaritin-induced cell cycle arrest and apoptosis in glioblastoma multiforme” [Biomed. Pharmacother. 100 (2018) 358–366]
- Retracted
- 1 April 2018
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 100, 358-366
RETRACTED: Activation of PPARγ mediates icaritin-induced cell cycle arrest and apoptosis in glioblastoma multiforme
- 1 April 2018
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 100, 358-366
RetractedRETRACTED: Activation of PPARγ mediates icaritin-induced cell cycle arrest and apoptosis in glioblastoma multiforme
- 19 November 2015
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 42 (12) , 1296-1307
Icaritin inhibits the invasion and epithelial‐to‐mesenchymal transition of glioblastoma cells by targeting EMMPRIN via PTEN/AKt/HIF‐1α signalling
Summary: Icaritin, a hydrolytic product of icariin from the Epimedium genus, exerts anti‐tumour effects on a variety of tumour cell types, mainly by inhibiting cell proliferation and inducing apoptosis. However, little is known about the role of icaritin in cancer invasion and epithelial‐to‐mesenchymal transition (EMT). In the present study, the glioblastoma (GBM) cell line U87MG was used as a model to investigate the effects of icaritin on the invasion and EMT of cancer cells. The results showed that icaritin significantly inhibited the invasion and EMT of GBM cells by targeting extracellular matrix metalloproteinase (EMMPRIN). Furthermore, the findings strongly indicate that the modulatory effect of icaritin on EMMPRIN is mediated via the PTEN/Akt/HIF‐1α signalling pathway. The data provide the first experimental evidence of the inhibitory effect of icaritin on cancer cell invasion and EMT, thus highlighting the potential of icaritin to be employed as a promising anti‐cancer agent in the treatment of GBM.
- 19 November 2015
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 42 (12) , 1296-1307
Icaritin inhibits the invasion and epithelial‐to‐mesenchymal transition of glioblastoma cells by targeting EMMPRIN via PTEN/AKt/HIF‐1α signalling
Summary: Icaritin, a hydrolytic product of icariin from the Epimedium genus, exerts anti‐tumour effects on a variety of tumour cell types, mainly by inhibiting cell proliferation and inducing apoptosis. However, little is known about the role of icaritin in cancer invasion and epithelial‐to‐mesenchymal transition (EMT). In the present study, the glioblastoma (GBM) cell line U87MG was used as a model to investigate the effects of icaritin on the invasion and EMT of cancer cells. The results showed that icaritin significantly inhibited the invasion and EMT of GBM cells by targeting extracellular matrix metalloproteinase (EMMPRIN). Furthermore, the findings strongly indicate that the modulatory effect of icaritin on EMMPRIN is mediated via the PTEN/Akt/HIF‐1α signalling pathway. The data provide the first experimental evidence of the inhibitory effect of icaritin on cancer cell invasion and EMT, thus highlighting the potential of icaritin to be employed as a promising anti‐cancer agent in the treatment of GBM.
- 11 January 2015
- Published by Springer Nature in Cell Biochemistry and Biophysics
- Vol. 72 (2) , 533-542
Icaritin Sensitizes Human Glioblastoma Cells to TRAIL-Induced Apoptosis
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been considered to be one of the most promising candidates in research on treatments for cancer, because it induces apoptosis in a wide variety of cancer cells but not in most normal human cell types. However, many cells including glioblastoma (GBM) cells are resistant to TRAIL-induced apoptosis, which limits the potential application of TRAIL in cancer therapy. Icaritin, a hydrolytic product of icariin from Epimedium Genus, has been identified as a potential therapeutic and preventive agent in renal cell carcinoma and breast cancer. In this study, we investigated whether Icaritin treatment could modulate TRAIL-induced apoptosis in GBM. The effect of icaritin on TRAIL sensitivity was assessed in human GBM U87 and U373 cells. The underlying regulatory cascades were approached by biochemical and pharmacological strategies. We found that nontoxic concentration of icaritin alone had no significant effect on the level of apoptosis, but a combination treatment of TRAIL and icaritin caused a significantly more profound apoptosis. The sensitization was accompanied by c-FLIP down-regulation and inhibition of NF-κB activity. Studies have further demonstrated that silencing NF-κB alone was sufficient to down-regulate c-FLIP expression and sensitized both tested cells to TRAIL-induced apoptosis. These data suggest that icaritin sensitizes TRAIL-induced tumor cell apoptosis via suppression of NF-κB-dependent c-FLIP expression, providing in vitro evidence supporting the notion that icaritin is a potential sensitizer of TRAIL in anticancer therapy against human GBM.
- 11 January 2015
- Published by Springer Nature in Cell Biochemistry and Biophysics
- Vol. 72 (2) , 533-542
Icaritin Sensitizes Human Glioblastoma Cells to TRAIL-Induced Apoptosis
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been considered to be one of the most promising candidates in research on treatments for cancer, because it induces apoptosis in a wide variety of cancer cells but not in most normal human cell types. However, many cells including glioblastoma (GBM) cells are resistant to TRAIL-induced apoptosis, which limits the potential application of TRAIL in cancer therapy. Icaritin, a hydrolytic product of icariin from Epimedium Genus, has been identified as a potential therapeutic and preventive agent in renal cell carcinoma and breast cancer. In this study, we investigated whether Icaritin treatment could modulate TRAIL-induced apoptosis in GBM. The effect of icaritin on TRAIL sensitivity was assessed in human GBM U87 and U373 cells. The underlying regulatory cascades were approached by biochemical and pharmacological strategies. We found that nontoxic concentration of icaritin alone had no significant effect on the level of apoptosis, but a combination treatment of TRAIL and icaritin caused a significantly more profound apoptosis. The sensitization was accompanied by c-FLIP down-regulation and inhibition of NF-κB activity. Studies have further demonstrated that silencing NF-κB alone was sufficient to down-regulate c-FLIP expression and sensitized both tested cells to TRAIL-induced apoptosis. These data suggest that icaritin sensitizes TRAIL-induced tumor cell apoptosis via suppression of NF-κB-dependent c-FLIP expression, providing in vitro evidence supporting the notion that icaritin is a potential sensitizer of TRAIL in anticancer therapy against human GBM.